Worth reading
24Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
2
LocationWording
Definitive
How definitive the wording is.This transaction
Name of transactionCounterparty (target company)株式会社ファインズファルマ
Disclosing companyMedical Ikkou Group Co.,Ltd.
Execution Date / Effective Date1 October 2026
Target company
Dispensing pharmacies, drugstores, and EC shop operations
Location Showa-ku, Nagoya, Aichi PrefectureShare capital ¥10 millionDate of incorporation November 2005
Impact on Business Performance
The impact of this transaction on the financial results of the Company's group is immaterial.
| Item | Details |
|---|---|
| Transaction name | Name of transaction |
| Counterparty name | 株式会社ファインズファルマ |
| Name of the Subject Company | 株式会社ファインズファルマ |
| Business Description of the Subject Company | Dispensing pharmacies, drugstores, and EC shop operations |
| Location of the Subject Company | Showa-ku, Nagoya, Aichi Prefecture |
| Capital Stock of the Subject Company | ¥10 million |
| Date of Establishment of the Subject Company | November 2005 |
| Impact on Business Performance | The impact of this transaction on the financial results of the Company's group is immaterial. |
| Execution Date / Effective Date | 1 October 2026 |
Items this document does not state (23)
Net Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Date of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Following extensive discussions between the two companies, the transaction was changed from the originally planned business acquisition to an absorption-type company split. The transfer of the 2 stores is intended to further grow the dispensing pharmacy business and strengthen its operating base.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.